title: Improved tolerability and quality of life with the new lopinavir/ritonavir tablet formulation.
authors.affiliation: Hospital de Bellvitge, L'Hospitalet de Llobregat, 08907 Barcelona, Spain. molmo@csub.scs.es
authors.forename: M
authors.initials: M
authors.lastname: Olmo
authors.forename: E
authors.initials: E
authors.lastname: Ferrer
authors.forename: J
authors.initials: J
authors.lastname: Curto
authors.forename: P
authors.initials: P
authors.lastname: Barragán
authors.forename: M
authors.initials: M
authors.lastname: Saumoy
authors.forename: N
authors.initials: N
authors.lastname: Perulero
authors.forename: D
authors.initials: D
authors.lastname: Podzamczer
mesh_terms: D000284:Administration, Oral; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D061466:Lopinavir; D011744:Pyrimidinones / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D011788:Quality of Life; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir